US Food and Drug Administration Commissioner Robert Califf kicked off the first meeting of the nascent Digital Health Advisory Committee (DHAC) held Wednesday and Thursday by emphasizing the difficulty of regulating generative AI.
Generative AI Devices The Focus Of First FDA Digital Health Advisory Committee Meeting
In its inaugural two-day meeting, the FDA Digital Health Advisory Committee discussed the promise of generative AI-enabled medical devices as well as challenges the agency faces in premarket evaluation, benefit/risk analysis, and postmarket monitoring.
More from Medtech Insight
More from Compliance
• By
Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.
• By
Data recently published in The BMJ found that almost 30% of device adverse event reports filed with the US FDA are late or missing accurate date information. A relatively small number of companies account for more than half of the late reports.
• By
Medtech Insight sat down with Arcadia's chief strategy officer Aneesh Chopra to discuss interoperability, industry standards and the future of health care data and AI.